Minerva Neurosciences (NASDAQ:NERV – Get Free Report) and OptiNose (NASDAQ:OPTN – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.
Valuation and Earnings
This table compares Minerva Neurosciences and OptiNose”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Minerva Neurosciences | N/A | N/A | -$30.00 million | $0.19 | 7.05 |
| OptiNose | $78.23 million | 1.16 | -$35.48 million | ($2.88) | -3.13 |
Minerva Neurosciences has higher earnings, but lower revenue than OptiNose. OptiNose is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Profitability
This table compares Minerva Neurosciences and OptiNose’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Minerva Neurosciences | N/A | N/A | -6.74% |
| OptiNose | -41.16% | N/A | -27.42% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Minerva Neurosciences and OptiNose, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Minerva Neurosciences | 0 | 1 | 0 | 0 | 2.00 |
| OptiNose | 0 | 3 | 0 | 0 | 2.00 |
Minerva Neurosciences currently has a consensus price target of $5.00, suggesting a potential upside of 273.13%. OptiNose has a consensus price target of $9.00, suggesting a potential upside of 0.00%. Given Minerva Neurosciences’ higher possible upside, analysts plainly believe Minerva Neurosciences is more favorable than OptiNose.
Institutional & Insider Ownership
34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 85.6% of OptiNose shares are held by institutional investors. 8.6% of Minerva Neurosciences shares are held by insiders. Comparatively, 2.3% of OptiNose shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Minerva Neurosciences beats OptiNose on 7 of the 10 factors compared between the two stocks.
About Minerva Neurosciences
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
About OptiNose
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
